United States · FDA National Drug Code directory
Daliresp
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 0310-0088_11cd495f-c5cf-4076-b69c-af202ec2a8a1
- Product NDC
- 0310-0088
- Form
- TABLET
- Composition / generic term
- roflumilast
- Labeler
- AstraZeneca Pharmaceuticals LP
- Marketing category
- NDA
- Marketing start / end (source format)
- 20150701
- Source listing expiry
- 20261231
Source-listed ingredients
- ROFLUMILAST — 250 ug/1
These values do not establish equivalence or a dose recommendation.
Packages
- 1 BLISTER PACK in 1 BOX, UNIT-DOSE (0310-0088-28) / 28 TABLET in 1 BLISTER PACK · 0310-0088-28
- 10 BLISTER PACK in 1 BOX, UNIT-DOSE (0310-0088-39) / 2 TABLET in 1 BLISTER PACK · 0310-0088-39
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →